Posted by Michael Wonder on 09 Jul 2018
NHS England says yes to Roche's Hemlibra
9 July 2018 - Roche’s new haemophilia A treatment Hemlibra has gained a valuable market access approval from NHS England.
The decision is just one of a slew of 'clinical commissioning policy' decisions NHS England announced on Friday, with 16 separate rulings on specialised medicines and other interventions unveiled.
While NICE is England’s best known market access gatekeeper, NHS England is in direct control of specialised commissioning, and negotiates directly on pricing and reimbursement on a select number of specialised and high cost medicines.
